Key Highlights

  • IDEXX Laboratories (NASDAQ:IDXX) traded at USD 661.00 on November 2, 2026, up 19.92% from a USD 551.21 close on October 30, after third-quarter results came out before the open.
  • Third-quarter Revenue was USD 1,214 million, up 10%, with diluted EPS of USD 4.01, per the company release, and published coverage cited consensus near USD 3.72, a figure that varied across summaries.
  • IDEXX lifted 2026 EPS guidance to USD 14.96 to USD 15.16 from USD 14.69 to USD 14.94, and revenue guidance to USD 4.741 billion to USD 4.767 billion from USD 4.700 billion to USD 4.745 billion.
  • Management estimated U.S. same-store clinical visits fell 1.8%, but about 4% net price gains and 1,904 inVue Dx placements offset that, pushing the installed base to nearly 11,000.

The Quarter and the Guidance Raise

IDEXX Laboratories (NASDAQ:IDXX) reported third-quarter 2026 results on Monday, November 2, before the market opened, with an analyst call at 8:30 a.m. ET. Revenue was USD 1,214 million, up 10%, and diluted EPS was USD 4.01. For comparison, second-quarter revenue was USD 1,217 million and EPS was USD 4.27, a sequential decline. The company raised full-year EPS guidance by about USD 0.25 at the midpoint to USD 14.96 to USD 15.16, and revenue guidance to USD 4.741 billion to USD 4.767 billion, with organic growth of 9.3 to 10.0%. Management said the revenue raise reflects Acquisition effects and strong recurring diagnostics revenue. Premarket quotes varied through the morning, from gains of about 17% to above 18%, before the screen showed 19.92%.

What Drove the Beat

Growth did not depend on pet traffic. Management said U.S. same-store clinical visits fell an estimated 1.8% in the quarter, while older pets, more testing per visit and about 4% net price improvement in recurring diagnostics lifted revenue. IDEXX placed 1,904 inVue Dx units, nearly half outside the United States, with an installed base near 11,000, and total premium instrument placements were 5,780. Management expects to exceed its 5,500 Placement goal for 2026. The company acquired CoVetAI on September 16, with terms undisclosed, and launched its Catalyst proBNP cardiac test for North American availability in October. The 2026 Operating Margin guide is 32.1 to 32.3%, and the fourth-quarter reported margin guide is 28.4 to 29.3%.

Valuation, Risks and What to Watch

At USD 661.00 the stock trades at about 43.9 times the USD 15.06 guidance midpoint, simple arithmetic, a premium multiple that leaves little room for a slip. Visit declines, weaker pet adoption, currency effects and the cost of instrument placements are the main sensitivities, and management itself pointed to a more challenging macro backdrop. Consensus figures differ across summaries, so the size of the beat should be read as approximate. The intraday gain can change by the close. The move is large for a company of this size. Watch the next visit data, inVue Dx placement pace and fourth-quarter guidance on margins.

Where Things Stand

The veterinary diagnostics leader is IDEXX Laboratories (NASDAQ:IDXX), and it jumped 19.92% because Earnings beat expectations and management raised both EPS and revenue guidance for 2026. The quarter showed that recurring diagnostics, pricing and instrument placements can offset a 1.8% decline in visits. The valuation is rich at about 43.9 times the guidance midpoint, so execution matters. The next catalysts are visit trends, inVue Dx placements and the fourth-quarter margin guide, which is lower than the full-year figure.